# GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy

> **NCT01704274** · PHASE2 · COMPLETED · sponsor: **Dr. D. Robert Siemens** · enrollment: 43 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **OTHER:** Low Dose GTN 0.0285 mg/hr
- **OTHER:** High Dose GTN 0.057 mg/hr
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01704274
- **Lead sponsor:** Dr. D. Robert Siemens
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2017-01
- **Final completion:** 2019-12
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2024-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01704274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01704274, "GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01704274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*